Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Cooper

Showing results (111-120 of 144) with videos related to

Pageof 15
Sort By:
Scientific Reports|December 30, 2025
Limited therapeutic efficacy of N-acetyl-L-leucine in a mouse model of CLN1 diseaseEwa A Ziółkowska, Nicole A Pagán Torres, Hsintsung Chen, et al.
Molecular Therapy. Methods & Clinical Development|November 22, 2017
A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type ISteven Q Le, Shih-Hsin Kan, Don Clarke, et al.
The Lancet. Neurology|November 25, 2018
Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosisSara E Mole, Glenn Anderson, Heather A Band, et al.
Acta Neuropathologica Communications|October 19, 2017
Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neuronsLotta Parviainen, Sybille Dihanich, Greg W Anderson, et al.
Acta Neuropathologica|September 11, 2012
Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashionJacqueline C Mitchell, Philip McGoldrick, Caroline Vance, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 12, 2015
Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primatesCitra N Mattar, Andrew M S Wong, Klemens Hoefer, et al.
Acta Neuropathologica Communications|December 22, 2025
Enteric nervous system degeneration in human and murine CLN3 disease, is ameliorated by gene therapy in miceEwa A Ziółkowska, Letitia L Williams, Matthew J Jansen, et al.
Molecular Genetics and Metabolism|June 19, 2012
Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosisJie Hu, Jui-Yun Lu, Andrew M S Wong, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease miceKeigo Takahashi, Nicholas R Rensing, Elizabeth M Eultgen, et al.
Plos One|May 5, 2012
Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIBFiona L Wilkinson, Rebecca J Holley, Kia J Langford-Smith, et al.
Pageof 15

Showing results (111-120 of 144) with videos related to

Sort By:
Pageof 15
Scientific Reports|December 30, 2025
Limited therapeutic efficacy of N-acetyl-L-leucine in a mouse model of CLN1 diseaseEwa A Ziółkowska, Nicole A Pagán Torres, Hsintsung Chen, et al.
Molecular Therapy. Methods & Clinical Development|November 22, 2017
A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type ISteven Q Le, Shih-Hsin Kan, Don Clarke, et al.
The Lancet. Neurology|November 25, 2018
Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosisSara E Mole, Glenn Anderson, Heather A Band, et al.
Acta Neuropathologica Communications|October 19, 2017
Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neuronsLotta Parviainen, Sybille Dihanich, Greg W Anderson, et al.
Acta Neuropathologica|September 11, 2012
Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashionJacqueline C Mitchell, Philip McGoldrick, Caroline Vance, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 12, 2015
Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primatesCitra N Mattar, Andrew M S Wong, Klemens Hoefer, et al.
Acta Neuropathologica Communications|December 22, 2025
Enteric nervous system degeneration in human and murine CLN3 disease, is ameliorated by gene therapy in miceEwa A Ziółkowska, Letitia L Williams, Matthew J Jansen, et al.
Molecular Genetics and Metabolism|June 19, 2012
Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosisJie Hu, Jui-Yun Lu, Andrew M S Wong, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease miceKeigo Takahashi, Nicholas R Rensing, Elizabeth M Eultgen, et al.
Plos One|May 5, 2012
Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIBFiona L Wilkinson, Rebecca J Holley, Kia J Langford-Smith, et al.
Pageof 15